A Study to Assess the Tolerability of Ianalumab (VAY736) With Investigator's Choice Thrombopoietin Receptor Agonist (IC TPO-RA) in Patients With Primary Immune Thrombocytopenia (ITP)
for Primary Immune Thrombocytopenia (ITP)
Drug: Ianalumab
2 locations incl. Margate
Sponsor: Novartis Pharmaceuticals
Sex: All·Age: 18+
Code: NCT07421167·Phase 2·Recruiting